Drug development is entering a new era with gene therapies, multispecific antibodies, and RNA-based medicines driving innovation. These advances promise transformative treatments but also introduce complex challenges in bioanalysis, immunogenicity, and regulatory compliance. How can developers stay ahead?

In a recent interview, Dr. Michael Schwenkert shared insights on why collaboration matters more than ever. Success depends on partners who combine scientific depth with flexibility and responsiveness. His perspectives highlight strategies such as using cell-based models for functional relevance, integrating immune profiling early, and applying AI-driven approaches to anticipate regulatory needs. These trends are reshaping assay design and risk management across the development lifecycle.

For organizations seeking continuity and expertise, we provide integrated solutions and a partnership mindset that helps turn complexity into progress.

Read the full article to discover an expert's perspectives on emerging trends, the role of scientific partnership, and practical strategies for navigating the next generation of therapeutic innovation.